A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
Phase III Study to Investigate the Efficacy and Safety of CS1001 or Placebo in Combination with FP as First-Line Therapy in Subjects with Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
DRUG: CS1001+ Fluorouracil+Cisplatin|DRUG: Placebo+ Fluorouracil+Cisplatin
Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by BICR, or death due to any cause, whichever occurred first., Approximately 43 months from the time of randomization|Overall survival (OS), OS was defined as the time from randomization to death due to any cause., Approximately 43 months from the time of randomization
PFS assessed by investigators according to RECIST v1.1, PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by investigators, or death due to any cause, whichever occurred first., Approximately 43 months from the time of randomization|Objective response rate (ORR) assessed by BICR and investigators according to RECIST v1.1, ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR) or a Partial Response (PR) per RECIST 1.1., Approximately 43 months from the time of randomization|Duration of response (DoR) assessed by BICR and investigators according to RECIST v1.1, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first., Approximately 43 months from the time of randomization
Phase III Study to Investigate the Efficacy and Safety of CS1001 or Placebo in Combination with FP as First-Line Therapy in Subjects with Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma